Published: 08, Oct 2026

AI in Medical Imaging Market

AI in Medical Imaging Market Size, Share and Analysis By Component (Software, Hardware, Services), By Technology (Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Others), By Modality (CT Scan, MRI, X-Ray, Ultrasound, Nuclear Imaging), By Application (Neurology, Cardiology, Breast Screening, Pulmonology, Orthopedics, Others), By End User (Hospitals, Diagnostic Imaging Centers, Ambulatory Care Centers, Research Institutes, Others), and Regional Forecast Till 2034

Download Free Sample

Market Size (2025):

USD 2.05 Billion

CAGR (2026–2034):

31.2%

Report Pages:

165–175

Market Tables:

55–65

Table of Content

Get a free sample of this report

Overview

The global AI in Medical Imaging Market was valued at USD 2.05 billion in 2025 and is projected to reach USD 23.60 billion by 2034, growing at a CAGR of 31.2% during the forecast period (2026–2034). The market is driven by rising diagnostic imaging volumes, a persistent global shortage of radiologists, and expanding regulatory clearances for AI-enabled detection, triage, and reporting tools across radiology, cardiology, and pathology workflows. The market is shifting from conventional, single-finding, single-modality algorithms toward comprehensive, foundation-model-based platforms capable of triaging multiple acute conditions from a single CT or X-ray study within one regulatory submission. Vendors are increasingly bundling detection, prioritization, quantification, and draft-reporting capabilities into unified operating systems that plug directly into hospital picture archiving and communication systems, reducing integration friction and accelerating adoption across community and academic health systems alike. Government initiatives such as the U.S. Food and Drug Administration's predetermined change control plan framework for adaptive AI and machine-learning-based software are easing the regulatory burden on developers by allowing cleared algorithms to be updated without repeat 510(k) submissions, encouraging continuous model improvement. In parallel, the European Union's Artificial Intelligence Act classifies diagnostic imaging AI as a high-risk application requiring conformity assessment, pushing vendors toward more rigorous validation and post-market surveillance practices that are gradually becoming a global benchmark. By Region, North America held the dominant share of the AI in medical imaging market in 2025, supported by the highest concentration of FDA-cleared algorithms and rapid hospital adoption. Asia-Pacific is projected to grow at the fastest pace through 2034, supported by expanding diagnostic imaging infrastructure, rising patient volumes in China and India, and growing government support for digital health screening programs.

Market Size & Share

CAGR (2026–2034):

Market Snapshot

Study Period:	2021-2034
Market Size in 2025:	USD 2.05 Billion
Market Size in 2026:	USD 2.69 Billion
Market Size by 2034:	USD 23.60 Billion
Unit Value:	USD Billion
Projected CAGR:	31.2% (2026–2034)
Largest Region:	North America
Fastest-Growing Region:	Asia-Pacific
Fastest-Growing Application:	Breast Screening

Market Dynamics

KEY MARKET TREND

Adoption of Foundation-Model and Generative AI Platforms Transforming Radiology Workflows

Radiology AI vendors are moving away from single-finding algorithms toward foundation models trained on millions of scans that can simultaneously flag more than a dozen acute conditions from one imaging study. This consolidation reduces the number of point solutions a hospital must integrate and validate, easing deployment across emergency and inpatient imaging workflows.
Generative AI is being layered onto detection algorithms to automatically draft preliminary radiology report text from chest radiographs and other studies, aiming to return interpretation time to radiologists facing rising case volumes. Early deployments position these drafting tools as an assistive second step following triage rather than a replacement for physician sign-off.
Large diagnostic imaging manufacturers are embedding AI-enabled reconstruction and enhancement engines directly into scanner hardware, allowing shorter acquisition times and reduced radiation or contrast dose without sacrificing image quality. This hardware-software convergence is expanding the addressable AI market beyond stand-alone software into next-generation imaging equipment sold as a bundled offering.
FDA data covering the first quarter of 2026 shows a cumulative 1,524 AI-enabled medical devices authorized since the agency began tracking these approvals in 1995, of which roughly three-quarters are radiology applications. The steady increase in authorization volume each quarter signals that regulators are keeping pace with a rapidly expanding pipeline of foundation-model and multi-finding imaging algorithms.

KEY MARKET DRIVER

Rising Diagnostic Imaging Volumes and Persistent Radiologist Shortages Are Driving Market Growth

Hospitals worldwide are performing a growing number of CT, MRI, and X-ray examinations each year, a trend accelerated by aging populations and expanding screening programs for cancer and cardiovascular disease. This rising imaging volume is outpacing the growth in trained radiologists, creating structural demand for AI tools that can triage and prioritize studies automatically.
A widening shortage of subspecialty radiologists in both developed and emerging markets is lengthening report turnaround times and increasing the risk of delayed diagnosis for time-sensitive conditions such as stroke and pulmonary embolism. Health systems are turning to AI-based triage software to flag critical findings immediately after image acquisition, ahead of formal radiologist review.
Regulatory agencies have accelerated clearance pathways for computer-aided detection and triage software, giving hospital procurement teams greater confidence to deploy AI tools at scale across emergency and outpatient imaging departments. This expanding base of cleared, clinically validated algorithms is lowering the adoption barrier that previously slowed AI purchasing decisions.
A Neiman Health Policy Institute analysis found that outpatient imaging interpretation turnaround times more than doubled between 2014 and 2023, with the steepest increases occurring in the most recent two years. The finding was cited by Aidoc in its June 2026 announcement of FDA Breakthrough Device Designation for an AI reporting tool aimed directly at this bottleneck

KEY MARKET OPPORTUNITY

Expansion of AI-Enabled Imaging Access in Underserved and Emerging Markets Creates Significant Opportunity

Handheld and portable ultrasound devices embedded with AI guidance are lowering the skill barrier for obtaining diagnostic-quality images in rural clinics and low-resource settings that lack trained sonographers. This is opening a new customer base among community health centers and mobile health programs that previously had no access to advanced imaging interpretation.
Chest X-ray AI tools built for tuberculosis and pneumonia triage are being deployed across community screening programs in Asia and Africa, supported by international health bodies seeking to close diagnostic gaps in regions with very few radiologists per capita. This creates a volume-driven, subscription-based revenue opportunity distinct from the premium hospital markets of North America and Europe.
As more AI imaging tools earn dedicated reimbursement codes and value-based payment recognition, vendors gain a path to sustainable, per-scan revenue rather than one-time software licensing, improving the long-term economics of building specialty-specific algorithms. This reimbursement momentum is expected to draw further investment into narrower, high-precision imaging AI applications over the next several years.
Qure.ai's chest X-ray tool qXR became the first AI-enabled tuberculosis screening solution to receive regulatory clearance for children aged zero to three in October 2025, extending its coverage across the entire pediatric population and building on guidance already cited twice in World Health Organization tuberculosis screening documents. The clearance illustrates how imaging AI vendors are targeting age groups and disease burdens concentrated in lower-income regions with limited radiologist access.

AI in Medical Imaging Market Size, 2025–2034 (USD Billion)

Segmentation Analysis

Analysis by Component

Software held the largest share of the AI in medical imaging market in 2025 because diagnostic algorithms, triage engines, and reporting platforms represent the core intellectual property that hospitals license on a per-scan or subscription basis, while imaging hardware and integration services generate comparatively smaller recurring revenue. Vendors such as Aidoc, Viz.ai, and Lunit generate the overwhelming majority of their revenue from cloud-hosted or on-premises software licenses rather than physical equipment. Continuous algorithm updates, expanding indication coverage, and multi-year enterprise licensing agreements with large hospital networks are reinforcing software's position as the anchor component of nearly every AI imaging deployment across radiology, cardiology, and pathology departments worldwide.

Services are projected to grow at the fastest CAGR during the forecast period as hospitals increasingly require implementation, PACS integration, algorithm validation, and ongoing performance-monitoring support to operate multi-vendor AI portfolios safely at scale. Health systems adopting foundation-model platforms need dedicated onboarding, workflow customization, and governance services to manage continuous model updates without disrupting clinical operations. Growing regulatory expectations around post-market surveillance of adaptive algorithms are also pushing vendors to expand managed-service offerings, creating a services layer that is scaling faster than software licensing revenue as deployments mature from pilot to enterprise-wide rollout.

Component categories include

· Software (Dominating Segment)

· Services (Highest CAGR Segment)

· Hardware

Analysis by Technology

Deep learning held the largest share of the AI in medical imaging market in 2025, supported by its proven ability to extract complex spatial patterns from CT, MRI, X-ray, and ultrasound images with accuracy that often exceeds earlier machine-learning approaches. Convolutional neural network architectures underpin the large majority of FDA-cleared imaging algorithms available today, from stroke detection to mammography screening. Continuous advances in model architecture, combined with growing volumes of annotated clinical imaging data available for training, are reinforcing deep learning's dominant position as the technical foundation on which nearly every commercial radiology and pathology AI product is built.

Natural language processing is projected to grow at the fastest CAGR through 2034 as vendors extend imaging AI beyond pixel-level detection into automated generation of structured radiology reports from detected findings. Tools that draft preliminary report text directly from chest radiographs and CT studies are being positioned to relieve reporting bottlenecks created by rising imaging volumes and radiologist shortages. As foundation models increasingly combine image interpretation with report-language generation in a single workflow, natural language processing is moving from a peripheral feature to a core differentiator for vendors competing for enterprise-wide radiology contracts.

Technology categories include

· Deep Learning (Dominating Segment)

· Natural Language Processing (Highest CAGR Segment)

· Machine Learning

· Computer Vision

· Others

Analysis by Modality

CT scan held the largest share of the AI in medical imaging market in 2025, reflecting the modality's central role in emergency, oncology, and cardiovascular imaging where speed of interpretation directly affects patient outcomes. The majority of FDA-cleared triage algorithms, including stroke, pulmonary embolism, and intracranial hemorrhage detection tools, are built specifically for CT data because of its high spatial resolution and widespread availability in emergency departments. Continued growth in whole-body and cardiac CT protocols, combined with expanding foundation-model coverage of multiple acute findings from a single CT study, is sustaining CT's leadership across the modality segment.

Ultrasound is projected to grow at the fastest CAGR among imaging modalities through 2034, driven by the rapid adoption of handheld, semiconductor-chip-based probes that pair portable hardware with AI-guided image acquisition and interpretation. These devices are lowering the skill barrier for obtaining diagnostic-quality images outside traditional radiology departments, including obstetric, cardiac, and emergency point-of-care settings in both developed and resource-limited regions. Regulatory clearances for AI tools such as automated gestational-age estimation and cardiac function assessment are expanding ultrasound's clinical use cases well beyond its traditional role, accelerating its growth relative to fixed imaging systems.

Modality categories include

· CT Scan (Dominating Segment)

· Ultrasound (Highest CAGR Segment)

· MRI

· X-Ray

· Nuclear Imaging

Analysis by Application

Neurology held the largest share of the AI in medical imaging market in 2025, supported by the clinical urgency of conditions such as ischemic stroke, intracranial hemorrhage, and large-vessel occlusion, where minutes of delay materially affect patient outcomes. AI-based neuro-imaging triage tools have among the longest clinical evidence base of any imaging AI category, with multiple peer-reviewed studies documenting reduced door-to-treatment times in stroke centers. Broad hospital network deployments of stroke and neuro-trauma triage software across thousands of sites worldwide continue to anchor neurology as the leading clinical application for AI in medical imaging.

Breast screening is projected to grow at the fastest CAGR among clinical applications during the forecast period, supported by rising global mammography screening volumes and mounting clinical evidence that AI-assisted second-reading and triage tools improve cancer detection rates while reducing radiologist workload. Consolidation among breast-imaging AI vendors, including recent acquisitions that combined complementary detection, density-assessment, and workflow-orchestration platforms into single portfolios, is accelerating commercial scale and international distribution. Expanding population-based screening programs in Europe and Asia-Pacific are further widening the addressable base for AI-enabled breast cancer detection technology.

Application categories include

· Neurology (Dominating Segment)

· Breast Screening (Highest CAGR Segment)

· Cardiology

· Pulmonology

· Orthopedics

· Others

Analysis by End User

Hospitals held the largest share of the AI in medical imaging market in 2025, reflecting their position as the primary site for acute, emergency, and inpatient imaging where AI-based triage delivers the most immediate clinical value. Large academic and community hospital networks have been the earliest and most extensive adopters of stroke, trauma, and multi-condition triage algorithms because they operate the imaging volumes and PACS infrastructure needed to justify enterprise-wide licensing. Continued expansion of hospital-based foundation-model platforms across CT and X-ray workflows is expected to keep hospitals as the anchor end-user segment through the forecast period.

Diagnostic imaging centers are projected to grow at the fastest pace among end users through 2034, supported by the consolidation of outpatient imaging networks that are standardizing AI-based detection and workflow tools across hundreds of sites simultaneously. Corporate imaging groups pursuing acquisitions of specialized AI vendors are able to deploy validated algorithms across their entire outpatient footprint faster than individual hospitals can achieve through standalone purchasing. Rising outpatient screening volumes for breast, lung, and cardiac disease are reinforcing diagnostic imaging centers as an increasingly important growth channel for AI-enabled detection software.

End User categories include

· Hospitals (Dominating Segment)

· Diagnostic Imaging Centers (Highest CAGR Segment)

· Ambulatory Care Centers

· Research Institutes

· Others

By Region

AI in Medical Imaging Market Regional Analysis

AI in Medical Imaging Market Share 2025, (CAGR)

Regional Analysis

North America held the dominant share of the AI in medical imaging market in 2025, supported by the largest concentration of FDA-cleared imaging algorithms of any region and rapid adoption across academic and community hospital networks in the United States. The U.S. Food and Drug Administration's active predetermined change control plan framework for adaptive AI and machine-learning-based software is giving developers a clearer regulatory pathway to update cleared algorithms, encouraging continued investment from both established imaging manufacturers and specialized AI vendors headquartered in the region. Canada is witnessing growing adoption of AI-based triage tools within provincial hospital networks facing radiologist shortages. Deep integration between AI vendors and major U.S. hospital systems, together with consolidation among outpatient imaging networks acquiring AI-enabled breast and pathology detection platforms, continues to reinforce North America's leadership position.

Asia-Pacific is projected to grow at the fastest CAGR in the AI in medical imaging market during the forecast period, driven by expanding diagnostic imaging infrastructure and rising patient volumes across China, India, Japan, and South Korea. China's national strategy to establish itself as a global leader in artificial intelligence is channeling government and private investment into domestic medical-imaging AI developers and hospital digitization programs. India has emerged as a hub for chest X-ray and tuberculosis-screening AI vendors serving both domestic public health programs and international markets with limited radiologist availability. South Korea's Lunit has achieved broad global deployment of its chest X-ray and mammography algorithms, while Japan's established imaging manufacturers continue to embed AI directly into next-generation scanner platforms sold across the region.

Countries and Regions Covered

North America (Dominating Region)

o United States (Largest Country Market)

o Canada

o Mexico

Europe

o Germany (Largest Country Market)

o France

o United Kingdom

o Italy

o Rest of Europe

Asia-Pacific (Fastest Growing Region)

o China (Largest Country Market)

o India (Fastest-Growing Country Market)

o Japan

o South Korea

o Rest of Asia-Pacific

Latin America

o Brazil (Largest Country Market)

o Chile (Fastest-Growing Country Market)

o Rest of Latin America

Middle East & Africa

o Saudi Arabia (Largest Country Market)

o United Arab Emirates (Fastest-Growing Country Market)

o Rest of Middle East & Africa

Market Share

The AI in medical imaging market is fragmented, combining large diagnostic imaging equipment manufacturers such as GE HealthCare, Siemens Healthineers, Koninklijke Philips, and Canon Medical Systems, which embed AI directly into scanner hardware, with a broad base of specialized software vendors including Aidoc, Viz.ai, Lunit, and RapidAI that focus on specific clinical indications. Consolidation is accelerating as larger diagnostic and digital-health platforms acquire complementary point solutions to build comprehensive, multi-modality AI portfolios rather than compete indication by indication. Key success factors include regulatory clearance breadth, integration depth with hospital PACS infrastructure, published clinical evidence, and the ability to bundle detection, triage, and reporting capabilities into a single enterprise contract. Leading companies are prioritizing foundation-model development, international regulatory expansion, and strategic acquisitions of complementary imaging AI and pathology platforms to broaden their addressable clinical use cases.

Key Players

· GE HealthCare Technologies Inc. (US)

· Siemens Healthineers AG (Germany)

· Koninklijke Philips N.V. (Netherlands)

· Canon Medical Systems Corporation (Japan)

· United Imaging Healthcare Co., Ltd. (China)

· Aidoc Medical Ltd. (Israel)

· RadNet, Inc. (US)

· Viz.ai, Inc. (US)

· Lunit Inc. (South Korea)

· Qure.ai Technologies Pvt. Ltd. (India)

· Harrison.ai Pty Ltd (Australia)

· HeartFlow, Inc. (US)

· Cleerly, Inc. (US)

· RapidAI, Inc. (US)

· Butterfly Network, Inc. (US)

· Tempus AI, Inc. (US)

· PathAI, Inc. (US)

· Nano-X Imaging Ltd. (Israel)

· Hologic, Inc. (US)

· Subtle Medical, Inc. (US)

Recent Market Developments

In June 2025, PathAI received U.S. FDA 510(k) clearance for its AISight Dx whole-slide imaging platform, extending regulatory-grade AI into primary diagnostic digital pathology workflows and broadening the clinical scope of AI-assisted cancer diagnosis beyond radiology into tissue-based pathology.
In July 2025, RadNet's wholly owned subsidiary DeepHealth completed its acquisition of iCAD, combining iCAD's ProFound Breast Health Suite with DeepHealth's SmartMammo platform to create one of the industry's broadest AI-enabled breast cancer detection and workflow portfolios, spanning more than 1,500 healthcare provider locations worldwide.
In March 2026, GE HealthCare received FDA 510(k) clearance for Photonova Spectra, a photon-counting CT platform built on its proprietary Deep Silicon detector technology, extending AI-enabled spectral imaging capability into a flexible, multi-configuration scanner line.
In January 2026, Aidoc received FDA clearance for its CARE Multi-Triage CT Body solution, combining eleven newly cleared indications with three existing ones into the first comprehensive foundation-model AI triage system cleared through a single regulatory submission.
In March 2026, Butterfly Network received FDA clearance for a fully automated Gestational Age Tool integrated into its handheld ultrasound platform, marking the first FDA-cleared blind-sweep ultrasound AI solution for estimating fetal gestational age in underserved maternal care settings.

Frequently Asked Questions

What is the AI in Medical Imaging Market?

The AI in Medical Imaging Market covers software, hardware, and services that apply machine learning, deep learning, and natural language processing to the acquisition, reconstruction, interpretation, and reporting of X-ray, CT, MRI, ultrasound, and nuclear imaging studies.